NCT04446806

Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

A Prospective Single Center Study of Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

With the introduction of all-trans-retinoic acid (ATRA) and arsenic,the outcome of patients with acute promyelocytic leukemia (APL)has been improved considerably over the last decades.However，early deaths (EDs), mainly due to APL-specific coagulopathy, differentiation syndrome (DS)emerge as a major threat to APL patients.We observe and evaluate the effectivity of induction therapy in patients with APL. Administrate intravenous dexamethasone to prevent or preemptive treat DS. Assess the efficacy and safety of ruxolitinib as second treatment in patients with severe DS with no respond to dexamethasone.Furthermore，the changes of spectrum of cytokines are monitered to find the relationship between the cytokines and the severity of DS.

Detailed description

Adults ages 18-75 with primary acute promyelocytic leukemia. Design: The induction therapy with ATRA 25mg/m2/d and ATO 10mg/kg/d should be started as soon as the diagnosis of APL confirmed. Intravenous dexamethasone at a dose of 5-20 mg daily must be started if the WBC count greater than 5e+9/L (before or during the treatment with ATRA) as prevention or preemptive therapy of DS. Idarubicin (4-10 mg/m2 /d\*3d) and hydroxyurea（1.0-3.0g/d）can be given as leukocyte lowering therapy which may lessen the risk of DS. When the progression of clinical symptoms of DS with no response to dexamethasone,ATRA must be stopped and ruxolitinib (5-20mg /d) should be administrated to reduce the production of cytokines. Participants should stay in the hospital during the treatment for about 4 weeks. The changes of spectrum of cytokines are monitored to discover the potential relationship between the cytokines and the severity of DS. Participants will visit every 1 months after CR for 3 years.

Conditions

• Safety and Efficacy

Interventions

Type	Name	Description
DRUG	Ruxolitinib	Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore

Timeline

• Start date: 2019-06-01
• Primary completion: 2020-12-31
• Completion: 2021-05-31
• First posted: 2020-06-25
• Last updated: 2020-06-25

Locations

1 site across 1 country: China